Skip to content

Realizing Effectiveness Across Continents With Hydroxyurea (REACH) Extension

Realizing Effectiveness Across Continents With Hydroxyurea: A Phase I/II Prospective Trial of Hydroxyurea for Children With Sickle Cell Anemia

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
PACTR
Registry ID
PACTR202411554524161
Enrollment
822
Registered
2024-11-18
Start date
2023-10-27
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders Paediatrics

Interventions

Hydroxyurea MTD
Hydroxyurea PK Dose

Sponsors

Cincinnati Childrens Hospital Medical Center
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Pediatric patients with documented sickle cell anemia (typically HbSS supported by hemoglobin electrophoresis, complete blood count, and peripheral blood smear) In the Original Cohort, age range of 1.00-9.99 years, inclusive, at the time of enrollment (now age 5.5 - 17.5 years); age range 3.0-10.0 years for the New Cohort Weight at least 10.0 kg at the time of enrollment Parent or guardian willing and able to provide written informed consent, with child's verbal assent as per local IRB/Ethics Board requirements Willingness to comply with all study-related treatments, evaluations, and follow-up

Exclusion criteria

Exclusion criteria: Known medical condition making participation ill-advised (e.g., acute or chronic infectious disease, HIV, or malignancy) Acute or chronic severe malnutrition determined by impaired growth parameters as defined by WHO (weight for length/height or height for age >3 z-scores below the median WHO growth standards. Pre-existing severe hematological toxicity (temporary exclusions) Anemia: Hb <4.0 g/dL Anemia: Hb <6.0 g/dL with ARC <100 x 109/L Reticulocytopenia: ARC <80 x 109/L with Hb <7.0 g/dL Thrombocytopenia: Platelets <80 x 109/L Neutropenia: ANC <1.0 x 109/L Blood transfusion within 60 days before enrollment (temporary exclusion) In the Original Cohort, hydroxyurea use within 6 months before enrollment (temporary exclusion). In the New Cohort, the children should be hydroxyurea naïve, without any prior treatment exposure.

Design outcomes

Primary

MeasureTime frame
Efficacy of long-term Hydroxyurea treatment at MTD

Secondary

MeasureTime frame
Reduction of malaria incidents while on hydroxyurea at MTD.;Success of PK-guided dosing of hydroxyurea

Countries

Angola, Congo, Kenya, Uganda

Contacts

Public ContactSusan Stuber

Project Manager CCHMC

susan.stuber@cchmc.org15136364200

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026